Brief: Actinium Pharmaceuticals Announces Phase 3 Sierra Trial Dosimetry Results
09/12/2019 11:21
Dec 9 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS ANNOUNCES PHASE 3 SIERRA TRIAL
DOSIMETRY RESULTS SUPPORT LOW DOSE IOMAB-B FOR TARGETED
LYMPHODEPLETION PRIOR TO ADOPTIVE CELL THERAPY
* ACTINIUM PHARMACEUTICALS INC - ACTINIUM IS ADVANCING
DEVELOPMENT
OF LOW DOSE IODINE-131 APAMISTAMAB
* ACTINIUM PHARMA - INTENDS TO ADVANCE ITS IOMAB-ACT PROGRAM
INTO
HUMAN PROOF-OF-CONCEPT CLINICAL TRIALS IN CONJUNCTION WITH AN
ADOPTIVE CELL THERAPY
Source text for Eikon: ID:nPn85WNYra
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities